Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

GSK Completes Recruitment in New COPD Study

March 13, 2014 9:17 am | News | Comments

GlaxoSmithKline plc and Theravance Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy,” known as SUMMIT, has completed enrollment. Read more...                 

Actavis Confirms Win in Generic Celebrex Suit

March 13, 2014 9:10 am | News | Comments

Actavis plc confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 is invalid. Read more...                       

Perrigo Launches Generic Neptazane for Ocular Conditions

March 13, 2014 9:06 am | News | Comments

Perrigo Co. announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. Read more...                       


Online Forum to Offer Global Discussion on Counterfeit Drug Regulations

March 13, 2014 9:00 am | News | Comments

Pharma IQ has announced their first Global Pharmaceutical Serialization and Track & Trace Open House will commence on the March 18. Read more...                             

Astellas Secures Isavuconazole Commercialization Rights in the U.S., Canada

March 13, 2014 2:25 am | by Astellas Pharma Inc. | News | Comments

Astellas Pharma Inc. announced that the company has amended the licensing agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. Astellas will now be responsible for all regulatory filings and will exclusively commercialize isavuconazole in the U.S. and Canada. Read more...

Pfizer Trial Shows Drug Prevents Community-Acquired Pneumonia

March 12, 2014 3:17 pm | News | Comments

Pfizer Inc. presented detailed results of CAPiTA, demonstrating that Prevenar 13 prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 years of age and older, the study’s primary objective. Read more...    

Chimerix Gets OK for Brincidofovir Pilot Trial, Gives Drug to Sick Boy

March 12, 2014 3:00 pm | News | Comments

Chimerix Inc. announced that it has reached agreement with the FDA for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. Josh Hardy, whose story brought public attention to adenovirus infection, will be the first person enrolled. Read more...

FDA Halts Geron's Imetelstat Development

March 12, 2014 1:46 pm | News | Comments

Geron Corp. announced that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold by the FDA, affecting all ongoing company-sponsored clinical trials. Read more...            


OxyContin Maker to Offer Abuse-Resistant Zohydro

March 12, 2014 11:25 am | News | Comments

The maker of OxyContin says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro. Read more...             

Senesco Launches New Cancer Trials in South Africa

March 12, 2014 11:19 am | News | Comments

Senesco Technologies Inc. reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Read more...                       

FDA Approves Xartemis XR Tablets for Pain Treatment

March 12, 2014 11:13 am | News | Comments

Mallinckrodt announced that the FDA has approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets for the management of acute pain severe enough to require opioid treatment. Read more...         

Oramed Granted Third Australia Patent for Oral Exenatide

March 11, 2014 11:00 am | News | Comments

Oramed Pharmaceuticals Inc. announced that IP Australia, the Australian government’s patent office, has issued the company its third patent in the country, for oral exenatide compositions made using the company's proprietary technology. Read more...

Scotland Approves Stelara for Psoriatic Arthritis

March 11, 2014 10:27 am | News | Comments

Janssen UK announced that the Scottish Medicines Consortium (SMC) has recommended the use of Stelara (ustekinumab) for the treatment of active psoriatic arthritis in adult patients in NHS Scotland. Read more...           


Omeros Announces Positive Data from Phase 2 aHUS Drug Trial

March 10, 2014 2:32 pm | News | Comments

Omeros Corp. announced positive data using OMS721 in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). Read more...     

Anti-psychotic Meds May Treat Glioblastoma

March 10, 2014 1:31 pm | News | Comments

Researchers have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. Read more...                    

FDA Accepts Lundbeck NDA Submission for IV Carbamazepine

March 10, 2014 1:19 pm | News | Comments

Lundbeck LLC announced that the FDA has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. Read more...     

Alexion Rises After Guidance Boost from Soliris Sales

March 10, 2014 12:51 pm | News | Comments

Alexion Pharmaceuticals raised its 2014 guidance on Monday, saying the national health agency of France will reimburse it for past sales of its drug Soliris. Read more...                       

Scottish Regulators Approve Zonegran for Adolescent Epilepsy

March 10, 2014 10:58 am | News | Comments

Zonegran (zonisamide) has been approved by the Scottish Medicines Consortium (SMC) for the treatment of partial epilepsy in adolescents and children aged six years and above in Scotland. Read more...               

Do ‘Sticky’ Cells Cause Cancer Drug Resistance?

March 10, 2014 10:25 am | News | Comments

Researchers have investigated the stickiness of leukemia cells and whether that stickiness is linked to drug resistance. Read more...                                  

Agenus, Ludwig to Advance Antibodies into Development

March 7, 2014 1:21 pm | News | Comments

Ludwig Cancer Research and Agenus Inc. announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. Read more...                  

Zyrtec Launched in New Dissolve Tabs

March 7, 2014 12:59 pm | News | Comments

The makers of Zyrtec are pleased to announce the launch of a new form to the Zyrtec portfolio of allergy-relief products– a convenient oral, dissolvable tablet. Read more...                      

Bill Allows Cannabis Oil for Epilepsy Treatment

March 7, 2014 12:50 pm | by Seanna Adcox | News | Comments

People suffering from severe epilepsy could legally use oil derived from marijuana, known as cannabidiol or CBD oil, under a bill advanced Thursday in the South Carolina House. Read more...               

Pfizer Recalls Effexor on Drug Mix Up

March 7, 2014 12:44 pm | News | Comments

Pfizer said Thursday it is recalling some lots of its antidepressant Effexor XR because a single capsule of a different medication, Tikosyn, was found in one bottle of the drug. Read more...               

J&J Settles Risperdal Suit for $5.9M

March 7, 2014 12:00 pm | by Matt Volz | News | Comments

Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with Montana over how an anti-psychotic drug was marketed, state Attorney General Tim Fox said Thursday. Read more...             

Novartis' Blood Cancer Drug Hits Primary Endpoint in Phase 3

March 7, 2014 9:47 am | News | Comments

Novartis announced that a pivotal Phase 3 trial of Jakavi (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control without the need for phlebotomy and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.